REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1565461
This article is part of the Research TopicMetabolic dysfunction-associated fatty liver disease (MAFLD): Innovative Management strategies using Herbal MedicinesView all 5 articles
Scutellaria baicalensis Georgi in Metabolic-associated Fatty Liver Disease Treatment: Research Progress
Provisionally accepted
- 1College of Health Management, Xihua University, Chengdu, China
- 2College of Food and Bioengineering, Xihua University, Chengdu, Sichuan Province, China
- 3Sichuan Vocational College of Chemical Technology, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Metabolic associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD), is a common liver condition marked by excessive fat accumulation exceeding 5% in the liver without significant alcohol consumption. It is closely linked to metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia, with a rising global prevalence projected to escalate from 25% to 56% over the next decade. The pathogenesis of MAFLD is multifaceted, involving insulin resistance, inflammation, and oxidative stress, with progressive symptoms that can lead to severe liver conditions including non-alcoholic steatohepatitis (NASH). Current treatment options are limited, as established medications show variable efficacy and safety. Scutellaria baicalensis Georgi（S. baicalensis）a traditional Chinese herb rich in flavonoids, has garnered attention for its potential therapeutic effects on MAFLD. Its pharmacological activities, including anti-inflammatory, antioxidant, and lipid-regulating properties, position S. baicalensis as a promising candidate for MAFLD management. This article reviews the latest research progress of S. baicalensis in the treatment of MAFLD, explores its mechanism of action, pharmacokinetics, and the development of related products, aiming to clarify the pathogenesis of MAFLD and promote the development of new treatment and prevention strategies based on traditional Chinese medicine.
Keywords: Metabolic associated fatty liver disease, Scutellaria baicalensis Georgi, Pharmacological activities, pharmacokinetics, Production development
Received: 23 Jan 2025; Accepted: 20 May 2025.
Copyright: © 2025 Chen, Liu, Zhao, Liu, Dong, Lou, Huang, Li and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liping Chen, College of Health Management, Xihua University, Chengdu, China
Guoying Huang, Sichuan Vocational College of Chemical Technology, Luzhou, China
Ling Li, College of Food and Bioengineering, Xihua University, Chengdu, Sichuan Province, China
Yuxin He, College of Food and Bioengineering, Xihua University, Chengdu, Sichuan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.